**Specifications table**TableSubject area*Biology*More specific subject area*Genetics*Type of data*Tables*How data was acquired*Next Generation Sequencing*Data format*analyzed*Experimental factors*DNA was extracted from FFPE-tumor samples and interlaboratory test samples for further analysis*Experimental features*Next Generation Sequencing was performed to determine the presence of pathogenic mutations, which have an impact on therapeutic decisions*Data source location*Cologne, Germany*Data accessibility*with this article*

**Value of the data**•**Common and rare mutations were detected, information on rare mutations could be of interest for further studies on specific mutations.**•**Many mutations classified as non-pathogenic are detected alongside the analysis of pathogenic mutations, impact of those alterations on therapy is not fully known so far.**•**Repeatability of the assay is given also for non-pathogenic mutations.**

1. Data {#s0005}
=======

The data represented here is additional data from our pre-clinical validation study (1). [Table 1](#t0005){ref-type="table"} shows the mutations, which were detected by NGS in the samples used for a clinical pre-validation in our laboratory. In total 107 pathogenic mutations were detected in the 121 samples tested successfully. 38 different mutations were detected: 4 different mutations in BRAF, 12 in EGFR, 2 in KIT, 9 in KRAS, 5 in NRAS, and 6 in PIK3CA. Common mutations as KRAS c.35G\>A (p.G12D), BRAF c.1799T\>A (p.V600E) or EGFR c.2573T\>G (p.L858R) could be detected as well as more uncommon mutations (e.g. KRAS c.351A\>T (p.K117N) or NRAS c.437C\>T (p.A146V)). [Table 2](#t0010){ref-type="table"} shows mutations, classified as non-pathogenic so far, which were detected in samples used for the testing of the repeatability of the GeneRead QIAact Actionable Insights Tumor Panel. 24 genetic alterations were detected in the Multiplex reference standard; nine respectively eight alterations were detected in the two clinical samples. Except for one mutation, which had a percentage of a mutant (PM) in the background of wild type in the range of the limit of detection, all mutations could be detected with similar frequencies in all five repetitions.Table 1Detected mutations. The table shows the mutations which were detected by NGS in the tested samples. Mutations were detected in BRAF, EGFR, KIT, KRAS, NRAS, and PIK3CA.Table 1:**GeneNucleotide substitution/ Amino Acid substitutionTotal%Clinical specimenInterlaboratory test samplesTotal1071004463BRAFTotal1816,82711**c.1397G\>C/ p.G466A10,931--c.1406G\>C/ p.G469A10,931--c.1799T\>A/ p.V600E1312,1549c.1798_1799delGTinsAA/ p.V600K32,8012**EGFRTotal3936,451029**c.2127_2129delAAC/ p.E709_T710delinsD10,93--1c.2156G\>C/ p.G719A10,931--c.2254_227delTCTCC/ p.S725_I759del10,931--c.2222C\>T/ p.P741L10,931--c.2237_2255delAATTAAGAGAAGCAACATCinsT/ p.E746_S752delinsV32,8012c.2235_2249delGGAATTAAGAGAAGC/ p.E746_A750del32,803--c.2248G\>C/ p.A750P10,93--1c.2281G\>A/ p.D761N10,93--1c.2369C\>T/ p.T790M1211,21111c.2573T\>G/ p.L858R1110,28--11c.2582T\>A/ p.L861Q10,931--c.2596G\>A/ p.E866K10,931--**KITTotal21,8711**c.1509_1510insGCCTAT/ p.Y503_F504insAY10,931--c.2447A\>T/p.D816V10,93--1**KRASTotal2927,101910**c.34G\>A/ p.G12S10,93--1c.34G\>T/ p.G12C21,872--c.35G\>A/ p.G12D43,744--c.35G\>C/ p.G12A21,8711c.35G\>T/ p.G12V98,4163c.38G\>A/ p.G13D43,7422c.183A\>T/ p.Q61H43,7422c.351A\>T/ p.K117N10,931--c.436G\>A/ p.A146T21,8711**NRASTotal98,4136**c.35G\>A/ p.G12D10,93--1c.181C\>A/ p.Q61K10,93--1c.182A\>G/ p.Q61R10,931--c.182A\>T/ p.Q61L54,6714c.437C\>T/ p.A146V10,931--**PIK3CATotal109,3546**c.1633G\>A/ p.E545K54,6723c.317_318delGCinsTT/ p.G106V10,931--c.331A\>G/ p.K111E10,931--c.3140A\>G/ p.H1047R10,93--1c.3129G\>T/ p.M1043I10,93--1c.263G\>A/ p.R88Q10,93--1Table 2Non-pathogenic mutations detected with NGS in samples used to determine the precision. Several alterations not known to have therapeutically impact so far were detected with NGS.Table 2:**SampleMutationDetected frequency of mutation \[%\]MeanSDRepetition 1Repetition 2Repetition 3Repetition 4Repetition 5Multiplex reference standard**ALKc.2535T\>C/ p.G845G828084848382,601,50ALKc.3036G\>A/ p.T1012T127,3412101210,671,84ALKc.4338C\>T/ p.T1446T333133303432,201,47ALKc.4472A\>G/ p.K1491R121110118,9810,601,03BRAFc.1929A\>G/ p.G643G181921212019,801,17EGFRc.1968C\>T/ p.H656H8,646,786,0275,956,880,97EGFRc.474C\>T/ p.N158N807978808179,601,02EGFRc.2361G\>A/ p.Q787Q141616161515,400,80ERBB2c.1963A\>G/ p.I655V373333343334,001,55ERBB2c.3508C\>G/ p.P1170A201816192219,002,00ERBB3c.3355A\>T/ p.S1119C343430303332,201,83ESR1c.1369+13777T\>G108,771391010,151,51ESR1c.30T\>C/ p.S10S16212498,7915,766,16KITc.2362-77G\>A323530312931,402,06KITc.2586G\>C/ p.L862L8,368,78,999,239,38,920,35PDGFRAc.1432T\>C/ p.S478P8,859,448,618,098,28,640,49PDGFRAc.1701A\>G/ p.P567P100100100100100100,000,00PDGFRAc.1809G\>A/ p.A603A201715171717,201,60PDGFRAc.2472C\>T/ p.V824V181514152016,402,24PDGFRAc.612T\>C/ p.N204N9,28,68108,918,349,030,56PDGFRAc.939T\>G/ p.G313G8,717,998,888,64108,840,65PIK3CAc.-76-14537C\>G495049544850,002,10PIK3CAc.-77+8483C\>T6,727,547,097,57,37,230,30PIK3CAc.1173A\>G/ p.I391M106,498,0811109,111,62**Tumor sample 1**KRASc.\*2505T\>G474746505148,201,94ALKc.2535T\>C/ p.G845G444343444443,600,49ALKc.4472A\>G/ p.K1491R585657555856,801,17EGFRc.2361G\>A/ p.Q787Q475152484849,201,94EGFRc.474C\>T/ p.N158N504951535050,601,36EGFRc.2184+19G\>A4,96--5,5----5,230,27EGFRc.1881-781C\>T495450495050,401,85ERBB2c.3508C\>G/ p.P1170A515246534850,002,61PDGFRAc.1701A\>G/ p.P567P10010099989999,200,75**Tumor sample 2**ALKc.2535T\>C/ p.G845G474745414344,602,33ALKc.4472A\>G/ p.K1491R434643474645,001,67EGFRc.474C\>T/ p.N158N414045444242,401,85EGFRc.2361G\>A/ p.Q787Q999998999998,800,40ERBB2c.3508C\>G/ p.P1170A474746514647,401,85ESR1c.30T\>C/ p.S10S9910010010010099,800,40KITc.2362-77G\>A343336343734,801,47PDGFRAc.1701A\>G/ p.P567P100100100100100100,000,00

2. Experimental design, materials and methods {#s0010}
=============================================

122 samples were tested retrospectively to validate the use of the GeneReader System in our laboratory. One sample proofed to be not suitable for NGS testing and was excluded from the analysis. The GeneRead QIAact Actionable Insights Tumor Panel was used for target enrichment of ALK, BRAF, EGFR, ERBB2, ERBB3, ESR1, KIT, KRAS, NRAS, PDGFRA, PIK3CA, and RAF1. Following target enrichment, library preparation and clonal amplification was done using the GeneRead DNA Library Q Kit and the GeneRead Clonal Amp Q Kit. DNA quality and concentration was determined after target enrichment and library preparation with the QIAxcel DNA High Resolution Kit on the QIAxcel instrument. Sequencing was performed on the GeneReader instrument with the GeneRead Sequencing Q Kit. Qiagen Clinical Insight Software was used for analysis and interpretation of the results. Sequencing products are analyzed by comparison with the following reference sequences: NM_004304.4 (ALK), NM_004333.4 (BRAF), NM_005228.4 (EGFR), NM_004448.3 (ERBB2), NM_001982.3 (ERBB3), NM_001122742.1 (ESR1), NM_000222.2 (KIT), NM_004985.4 (KRAS), NM_002524.4 (NRAS), NM_006206.5 (PDGFRA), NM_006218.3 (PIK3CA), and NM_002880.3 (RAF1).
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Supplementary material

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2018.04.114](http://doi:10.1016/j.dib.2018.04.114){#ir0005}.
